Adjuvant activity of CpG-ODN formulated as a liquid crystal

SANCHEZ VALLECILLO M.; ULLIO GAMBOA G.; PALMA S.; HARMAN M.; CHIODETTI A.; MORÓN G.; ALLEMANDI D.; PISTORESI-PALENCIA M.C,; MALETTO B.

ELSEVIER SCI LTD

Lugar: Amsterdam; Año: 2014 vol. 35 p. 2529 - 2529

he adjuvants approved in human vaccine with recombinant/puri fi ed antigens induce weak cellular immune response and so the development of new adjuvant strategies is critical. CpG-ODN has suc- cessfully been used as an adjuvant (phase IeIII clinical trials) but its bioavailability needs to be improved. We investigated the adjuvant ability of CpG-ODN formulated with a liquid crystal nanostructure of 6-O-ascorbyl palmitate (Coa-ASC16). Mice immunized with OVA/CpG-ODN/Coa-ASC16 elicited a potent specific IgG1, IgG2a, Th1 and Th17 cellular response without systemic adverse effects. These responses were superior to those induced by OVA/CpG-ODN (solution of OVA with CpG-ODN) and to those induced by the formulation OVA/CpG-ODN/Al(OH)3. Immunization with OVA/CpG-ODN/Coa-ASC16 resulted in a long-lasting cell-mediated immune response (at least 6.5 months). Furthermore, Coa-ASC16 alone allows a controlled release of CpG-ODN in vitro and induces local in fl ammatory